WALTHAM, Mass.--(BUSINESS WIRE)--
Phase 1 Data for IMGN779 and IMGN632 to be Highlighted in Oral Presentations at ASH
ImmunoGen, Inc., (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that abstracts highlighting two of the Company’s experimental ADC therapies, IMGN779 and IMGN632, have been accepted for presentations at the upcoming American Society of Hematology (ASH) Annual Meeting to be held December 1-4 in San Diego, California.
Both IMGN779 and IMGN632 use ImmunoGen's novel indolino-benzodiazepine payloads called IGNs, which alkylate DNA without crosslinking. IGNs have been designed to have high potency against acute myeloid leukemia (AML) blasts, while demonstrating less toxicity to normal marrow progenitors than other DNA-targeting payloads.1 IMGN779 is a next-generation anti-CD33 ADC for the treatment of AML, currently in Phase 1 testing. IMGN632 is a CD123-targeting ADC for hematological malignancies, including AML and blastic plasmacytoid dendritic cell neoplasm (BPDCN), and is also in Phase 1 testing.
In an oral presentation, safety and anti-leukemia activity findings from the ongoing dose escalation study of IMGN779 in patients with relapsed or refractory AML will be reported. In a separate oral presentation, initial safety and anti-leukemia activity findings from the dose escalation stage of the first-in-human trial of IMGN632 will be reported. Preclinical data related to IMGN632 will also be presented in poster sessions.
- Title (Abstract #26): “Maturing Clinical Profile of IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Acute Myeloid Leukemia”
- Oral session 613: Saturday, December 1, 2018, 7:45am PST
- Title (Abstract #27): “A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies”
- Oral session 613: Saturday, December 1, 2018, 8:00am PST.
- Title (Abstract #2647): “Synergistic anti-leukemia activity of PARP inhibition combined with IMGN632, an anti-CD123 antibody-drug conjugate in acute myeloid leukemia models”
- Poster session 604: Sunday, December 2, 2018, 6:00-8:00pm PST
- Title (Abstract #3956): “Pre-clinical efficacy of CD123-targeting antibody-drug conjugate IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) models”
- Poster session 605: Monday, December 3, 2018, 6:00-8:00pm PST
Additional information can be found at www.hematology.org, including abstracts.
Indolino-benzodiazepine cancer-killing agents, or IGNs, are a new class of cancer-killing agent developed by ImmunoGen for use in ADCs. These ultra-potent, DNA-acting IGNs alkylate DNA without crosslinking, which preclinically has resulted in potent anti-leukemia activity with relative sparing of normal hematopoietic progenitor cells.
IMGN779 is a novel ADC that combines a high-affinity, humanized anti-CD33 antibody, a cleavable disulfide linker, and one of ImmunoGen's novel indolino-benzodiazepine payloads, called IGNs, which alkylate DNA without crosslinking, resulting in potent preclinical anti-leukemia activity with relative sparing of normal hematopoietic progenitor cells. IMGN779 is in Phase 1 clinical testing for the treatment of AML.
IMGN632 is a novel, anti-CD123 antibody-drug conjugate that is a potential treatment for AML, BPDCN, and other CD123-positive malignancies. IMGN632 uses a novel humanized anti-CD123 antibody coupled via a peptide linker to a unique DNA-alkylating IGN payload. In preclinical models, IMGN632 has exhibited potent antitumor activity with a wide therapeutic index in AML, BPDCN, and acute lymphoblastic leukemia (ALL). IMGN632 is in Phase 1 clinical testing for the treatment of AML and BPDCN.
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to “target a better now.” Our lead product candidate, mirvetuximab soravtansine, is in a Phase 3 study for folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer, and in Phase 1b/2 testing in combination regimens. Our novel IGN candidates for hematologic malignancies, IMGN779 and IMGN632, are in Phase 1 studies.
Learn more about who we are, what we do, and how we do it at www.immunogen.com.
1Kovtun et al, abstract 768, ASH 2016.
This press release includes forward-looking statements based on management's current expectations. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. Various factors could cause ImmunoGen's actual results to differ materially from those discussed or implied in the forward-looking statements, and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this release. It should be noted that there are risks and uncertainties related to the development of novel anticancer products, including risks related to preclinical and clinical studies, their timings and results, and the potential that earlier clinical studies may not be predictive of future results. A review of these risks can be found in ImmunoGen's Annual Report on Form 10-K for the fiscal year ended December 31, 2017 and other reports filed with the Securities and Exchange Commission.